Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 6th Preview)
-
Frontline lymphoma win for Epkinly in first-line DLBCL
AbbVie and Genmab reported Phase 3 results showing their T-cell engager Epkinly (epcoritamab) plus standard chemotherapy cut the risk of disease progression or death by nearly half versus chemo alone in newly diagnosed diffuse large B-cell lymphoma. The companies positioned the dataset as a potential first-line approval path, setting up a direct competitive challenge to Roche’s Polivy. In the trial, Epkinly met the primary endpoint and delivered a 51% relative risk reduction in the intermediate- or high-risk population enrolled at 900 patients. Genmab also highlighted Epkinly’s current commercial traction, citing $312 million in global net sales in the first half of the year. The readout matters for patient access and treatment sequencing because bispecifics are increasingly moving earlier in hematologic oncology. It also renews scrutiny on how combination regimens balance efficacy against immune-related tolerability and monitoring needs as products scale beyond specialized centers.
-
FDA grants frontline CLL label expansion for Jaypirca (pirtobrutinib)
The FDA approved pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), based on the Phase 3 BRUIN CLL-313 trial. The decision expands the noncovalent BTK inhibitor’s use beyond relapsed settings and reinforces targeted therapy as first-line standard for appropriate CLL patients. In BRUIN CLL-313, pirtobrutinib significantly delayed disease progression versus bendamustine plus rituximab, with median progression-free survival not estimable versus 33.5 months in the comparator arm (HR 0.20). Overall survival was immature, with deaths still limited in both groups. The approval shifts treatment planning for older or comorbidity-heavy patients who may receive limited lines of therapy, increasing pressure on rivals to demonstrate competitive efficacy and durable safety in initial CLL regimens.
-
Vaxcyte’s VAX-31 clears Phase 3 endpoints in pneumococcal vaccine
Vaxcyte said its Phase 3 pneumococcal conjugate vaccine VAX-31 met key co-primary immunogenicity endpoints in adults, sending the company’s shares sharply higher. The result sets up a potential expansion of serotype coverage and further intensifies competition in the large, established pneumococcal vaccine market. Across a randomized Phase 3 study enrolling just over 3,500 adults age 50 and older, VAX-31 was compared with Pfizer’s Prevnar and Merck’s Capvaxive on antibody responses across multiple bacterial strains. Vaxcyte emphasized its 31-valent design as a differentiator for broader protection. For biotech investors and clinical planners, the readout is a near-term signal that next-generation pneumococcal coverage could continue to progress through regulatory pathways, with commercial implications for payers and healthcare systems managing vaccine portfolios by serotype breadth.
-
GE HealthCare to buy Sofie Biosciences to expand US PET radiopharmaceutical manufacturing
GE HealthCare agreed to acquire Sofie Biosciences for $945 million in cash, aiming to expand its US footprint in radiopharmaceutical manufacturing and distribution for PET tracers. The deal is expected to close in the first half of 2027 and would bring Sofie’s contract manufacturing network into GE HealthCare’s pharmaceutical diagnostics business. The acquisition strengthens access to F18-labeled PET products that require time-sensitive production and distribution, including GE HealthCare’s Flyrcado. GE HealthCare also said it will gain rights to FAPI-74, a pan-cancer PET radiotracer outside the US. Operationally, the transaction could reduce bottlenecks in radiopharmaceutical adoption by increasing capacity across 15 US CMO sites while preserving Sofie’s role as a manufacturing partner for customers during and after the transition.
-
Caribou pauses development and reviews strategic alternatives for CAR-T programs
Caribou Biosciences said it is evaluating strategic alternatives and plans to discontinue development of its two donor-derived CAR-T programs, citing difficulty securing capital despite FDA alignment on the Phase 3 design for vispa-cel. The board-approved review includes potential merger, acquisition, or other business combinations involving Caribou or its assets. The planned development halt would stop further clinical work for vispa-cel in relapsed or refractory B-cell non-Hodgkin lymphoma and for CB-011 in relapsed or refractory multiple myeloma. Caribou reported cash and marketable securities of $113.8 million as of June 30, 2026 and outlined cost reductions plus a workforce reduction mostly complete in Q4 2026. The move highlights how financing constraints can abruptly end late-stage CAR-T ambitions even when regulatory groundwork is in place, potentially redirecting patient opportunity and competitive dynamics across the space.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.